Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
…
continue reading
1
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA"?
13:06
13:06
Play later
Play later
Lists
Like
Liked
13:06
From ASCO 2024 The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FDA) approval is typically longer than a decade. “There has to be a better way,” says Bob T. Li, MD, PhD, MPH, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City and associate…
…
continue reading
1
"Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More
12:32
12:32
Play later
Play later
Lists
Like
Liked
12:32
From ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas. "Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More.
…
continue reading
1
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"
10:29
10:29
Play later
Play later
Lists
Like
Liked
10:29
From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center. Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"
…
continue reading
1
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says
25:13
25:13
Play later
Play later
Lists
Like
Liked
25:13
From ASCO 2024 New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says. Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden University
…
continue reading
1
Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"
10:46
10:46
Play later
Play later
Lists
Like
Liked
10:46
From ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center. Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"
…
continue reading
1
Oncologist Shortage “Has Gotten to the Crisis Level”
10:02
10:02
Play later
Play later
Lists
Like
Liked
10:02
Especially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Cancer Center of Middle Georgia in Dublin. “We just don’t have enough supply of medical oncologists/hematologists,” he tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology a…
…
continue reading
1
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
9:20
9:20
Play later
Play later
Lists
Like
Liked
9:20
The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A. Figlin, MD, the Steven Spiel…
…
continue reading
1
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
10:34
10:34
Play later
Play later
Lists
Like
Liked
10:34
Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced? “It’s better to have choices than not,” explains Paul Bunn, MD, the Dudley Chair in Cancer Research at the University of Colorado in Aurora. Dr. Bunn discuss…
…
continue reading
1
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
11:16
11:16
Play later
Play later
Lists
Like
Liked
11:16
The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. Data from the recent EMBARK trial have changed practice for…
…
continue reading
1
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”
11:26
11:26
Play later
Play later
Lists
Like
Liked
11:26
The U.S. Food and Drug Administration’s recent accelerated approval of a tumor-infiltrating lymphocyte therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Center. Dr. Weber, who was part of the team to first work …
…
continue reading
1
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care
10:48
10:48
Play later
Play later
Lists
Like
Liked
10:48
Recent advances in metastatic urothelial carcinoma have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, deputy director of the UVA Cancer Center and professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville. From the recent approval of enfortumab vedotin plus pemb…
…
continue reading
1
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression
11:57
11:57
Play later
Play later
Lists
Like
Liked
11:57
Recent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast cancer that has progressed after frontline hormone therapy. Ruth M. O’Regan, MD, chair of medicine and Charles H. Dewey Professor at the University of Rochester in New York, highlights which recent dev…
…
continue reading
1
Controversies, Difficult Questions Arise in NSCLC Amid New Data
10:55
10:55
Play later
Play later
Lists
Like
Liked
10:55
Recent data on the use of immunotherapy and targeted treatments in patients with advanced non-small cell lung cancer (NSCLC) have introduced a myriad of questions. These include controversial topics and difficult decisions, like when to incorporate CTLA-4 inhibition and what patients can expect from immuno-oncology monotherapy in the metastatic set…
…
continue reading
1
What FDA Approval of Belzutifan Means for Kidney Cancer Care
10:08
10:08
Play later
Play later
Lists
Like
Liked
10:08
Belzutifan was recently approved by the U.S. Food and Drug Administration (FDA) for use in previously treated adults with advanced renal cell carcinoma. How should this drug best be incorporated into practice? Eric Jonasch, MD, professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Hous…
…
continue reading
1
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer
12:04
12:04
Play later
Play later
Lists
Like
Liked
12:04
CDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have been complicated by a lack of head-to-head trials. Dr. …
…
continue reading
1
Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023?
10:32
10:32
Play later
Play later
Lists
Like
Liked
10:32
From compelling data presented at the San Antonio Breast Cancer Symposium to the recent U.S. Food and Drug Administration approval of capivasertib, 2023 saw numerous key advances in breast cancer care. Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor at Harvard Medical …
…
continue reading
1
“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances
11:30
11:30
Play later
Play later
Lists
Like
Liked
11:30
From the use of prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) to advancements in targeted treatments, prostate cancer care is quickly evolving. Edwin M. Posadas, MD, director of the Experimental Therapeutics Program and director of the Center for Urologic Oncology Research Excellence at Cedars-Sinai in Los Angeles, sp…
…
continue reading
1
Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong Benefit
11:56
11:56
Play later
Play later
Lists
Like
Liked
11:56
Results of the recent EMBARK study show that both enzalutamide plus leuprolide and enzalutamide monotherapy significantly improved metastasis-free survival compared with leuprolide alone in patients with prostate cancer who have high-risk biochemical recurrence. Lead author Stephen Freedland, MD, associate director for education and training and di…
…
continue reading
1
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023
11:47
11:47
Play later
Play later
Lists
Like
Liked
11:47
Studies involving high-risk, early-stage ER-positive breast cancer are among the most eagerly anticipated at this year’s San Antonio Breast Cancer Symposium (SABCS), to be held Dec. 5-9. Virginia Kaklamani, MD, professor of medicine in the division of hematology and medical oncology at the University of Texas Health Sciences Center San Antonio and …
…
continue reading
1
Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learned
13:15
13:15
Play later
Play later
Lists
Like
Liked
13:15
Last month, a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) determined that progression-free survival (PFS) could not be reliably interpreted in a confirmatory clinical trial for sotorasib (Lumakras) used to treat KRAS G12C–mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Ravi A. Madan, …
…
continue reading
1
First-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy
9:15
9:15
Play later
Play later
Lists
Like
Liked
9:15
How should results of the FLAURA2 clinical trial be applied in practice? The study examined the use of osimertinib plus chemotherapy in the first-line treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared with osimertinib alone and found that progression-free survival was significantly improved with the combination treatmen…
…
continue reading
1
What Recent “Outstanding Results” in MCL Mean for Practice
11:13
11:13
Play later
Play later
Lists
Like
Liked
11:13
“Therapies are improving dramatically” in mantle cell lymphoma (MCL), according to Michael Wang, MD, professor in the department of lymphoma/myeloma, division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston. Dr. Wang presented updates on major advances in MCL at the recent Society of Hematologic Oncology (SOHO) an…
…
continue reading
1
The Quest to Cure CLL: “Remarkable” Results With New Strategy
16:00
16:00
Play later
Play later
Lists
Like
Liked
16:00
Recent advances have provided new options for when and how best to treat patients with chronic lymphocytic leukemia (CLL). Trials of combination strategies have shown promise in providing patients the potential for unmaintained remissions. Marco Ruella, MD, an assistant professor of medicine in hematology-oncology at the Perlman School of Medicine …
…
continue reading
1
Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice?
14:18
14:18
Play later
Play later
Lists
Like
Liked
14:18
The World Conference on Lung Cancer (World Lung) will be held in Singapore, September 9–12. The current president of International Association for the Study of Lung Cancer (IASLC), Heather A. Wakelee, MD, division chief of medical oncology at the Stanford Cancer Institute in California, shares which presentations and findings she is most looking fo…
…
continue reading
1
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations
15:07
15:07
Play later
Play later
Lists
Like
Liked
15:07
Updates to the American Society for Clinical Oncology’s (ASCO’s) living guidelines for therapy in patients with stage IV non-small cell lung cancer (NSCLC) with driver alterations were recently released. Dwight H. Owen, MD, MS, from The Ohio State University Comprehensive Cancer Center – James, examines the new recommendations that he and his team …
…
continue reading
1
More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists
13:24
13:24
Play later
Play later
Lists
Like
Liked
13:24
In early July, beloved surgeon and breast cancer advocate Susan Love, MD, MBA, died at age 75 years, after a recurrence of leukemia. Dr. Love’s legacy extends beyond the lives of her patients and into the approaches and attitudes of her fellow physicians. Stephanie Graff, MD, medical advisor to the Dr. Susan Love Foundation for Breast Cancer Resear…
…
continue reading
1
Will HER3 Targeting Change Breast Cancer Care?
12:43
12:43
Play later
Play later
Lists
Like
Liked
12:43
HER2 inhibitors dramatically changed care for many breast cancers; however, less is known about HER3, which acts in concert with HER2. Does HER3 have the same potential to reshape treatment strategies? Erika Hamilton, MD, director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville, talks with Bob Figlin…
…
continue reading
1
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now
13:36
13:36
Play later
Play later
Lists
Like
Liked
13:36
Although findings have suggested that adjuvant osimertinib is beneficial in early-stage non-smallcell lung cancer (NSCLC), some concerns have persisted. Balazs Halmos, MD, MS, associate director of clinical science, and director of both thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center in New York, says that “all t…
…
continue reading
1
“Don't Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer
13:21
13:21
Play later
Play later
Lists
Like
Liked
13:21
How should community oncologists best approach ESR1 mutations in breast cancer, given the latest findings? Recent data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and elsewhere have shed light on issues related to ESR1 testing and treatment selection. Bob Figlin, MD, the Steven Spielberg Family Chair in hematol…
…
continue reading
1
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?
11:57
11:57
Play later
Play later
Lists
Like
Liked
11:57
Recent results demonstrated that mRNA vaccination improved recurrence-free survival among patients with melanoma. This has led to questions about what’s next for this promising intervention. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars Sinai Cancer in Los Angeles, welcomes Jeffrey Weber, MD, PhD, deputy directo…
…
continue reading
1
“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice
11:44
11:44
Play later
Play later
Lists
Like
Liked
11:44
Within the last few years, an “explosion of data” regarding adjuvant and neoadjuvant treatment for resectable lung cancer has contained “major wins” for patient care. Although exciting, the rapid advancement has led to questions about when chemotherapy and chemoimmunotherapy should be adopted or avoided. Bob Figlin, MD, the Steven Spielberg Family …
…
continue reading
1
“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”
14:37
14:37
Play later
Play later
Lists
Like
Liked
14:37
As treatment options increase for patients with CLL, so do questions about which interventions, if any, are right for which patients and when. Bob Figlin, MD, and Nicole Lamanna, MD, discuss key considerations, ranging from cardiac toxicity to why Dr. Lamanna “won't just treat for a symptom.”
…
continue reading
1
Pragmatica-Lung Tests a Treatment and a New Approach to Trials
9:51
9:51
Play later
Play later
Lists
Like
Liked
9:51
The newly opened Pragmatica-Lung trial compares ramucirumab plus pembrolizumab versus usual care for treatment of stage IV or recurrent non-small cell lung cancer. The trial is designed to ease enrollment requirements and data collection needs, focusing on the key endpoint of overall survival. Listen as study lead Karen Reckamp, MD, professor and d…
…
continue reading
1
The Best First Step in Metastatic NSCLC Care
9:13
9:13
Play later
Play later
Lists
Like
Liked
9:13
With more than 10 known driver mutations in non-small cell lung cancer (NSCLC), testing is ever more critical, says Heather Wakelee, MD, division chief of medical oncology at Stanford University and president of the International Association for the Study of Lung Cancer. Listen as she and Peer-Spectives host Bob Figlin, MD, the Steven Spielberg Fam…
…
continue reading
1
Neo- and Adjuvant Treatments Are Changing Care in Early NSCLC
11:38
11:38
Play later
Play later
Lists
Like
Liked
11:38
Treatment options are expanding quickly in early non-small cell lung cancer. Listen as Heather Wakelee, MD, division chief of Medical Oncology at Stanford University and president of the International Association for the Study of Lung Cancer, describes how she’s using new agents and incorporating trial findings into practice. She and host Bob Figli…
…
continue reading
1
NALIRIFOX Changes Care in Pancreatic Cancer: Here’s How
10:42
10:42
Play later
Play later
Lists
Like
Liked
10:42
After a decade of limited gains in metastatic pancreatic cancer, Zev Wainberg, MD, professor of medicine and co-director of the GI oncology program at the University of California, Los Angeles, presented the results of the NAPOLI-3 trial at the ASCO Gastrointestinal Cancers Symposium last month. The data showed an improvement in overall survival an…
…
continue reading
1
Matching Breast Cancer Patients to Therapies: Here’s How
11:00
11:00
Play later
Play later
Lists
Like
Liked
11:00
The landscape for breast cancer treatment is shifting quickly, with an ever-increasingemphasis on targeted and hormonal therapies. Listen as Virginia Kaklamani,MD, professor of medicine in the division of hematology oncology at UT Health San Antonio, and medical directorof the breast oncologyprogram at UT Health San Antonio, MD Anderson Cancer Cent…
…
continue reading
1
Myelofibrosis Remains Tough to Treat, But New Drugs Are Paving the Way
13:46
13:46
Play later
Play later
Lists
Like
Liked
13:46
Listen as Gabriela Hobbs, MD, clinical director of the leukemia atMass General, talks with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer in Los Angeles, about the latest progress in the treatment of myelofibrosisand how she both assesses new patients and plans their treatment. New agents, including …
…
continue reading
1
KRAS Inhibition in NSCLC: When, How, and Why?
14:12
14:12
Play later
Play later
Lists
Like
Liked
14:12
Melissa Johnson, MD,a medical oncologist with Tennessee Oncology and Director of Lung Cancer Research at Sarah Cannon Research Institute in Nashville,joins host Robert Figlin, MD, Steven Spielberg Family Chair in HematologyOncologyat Cedars-Sinai Cancer, to talk about KRAS G12C inhibition in non-small cell lung cancer (NSCLC)treatment. She talks ab…
…
continue reading
1
Strategies for Navigating a Hematology/Oncology Fellowship
14:07
14:07
Play later
Play later
Lists
Like
Liked
14:07
The key steps to launching a successful and professionally fulfilling hematology/oncology fellowship is to “reflect, project, and adapt,” according to Gerald Hsu, MD, PhD, associate clinical professor of medicine and director of the Hematology/Oncology Fellowship Program at UCSF. Dr. Hsu spoke with Robert Figlin, MD, to discuss how new fellows can …
…
continue reading
Tejas Patil, MD, assistant professor of medical oncology at the University of Colorado Cancer Center, talks with Robert A. Figlin, MD, about new targeted therapies for non-small cell lung cancer (NSCLC), particularly tepotinib (Tepmetko) for MET exon 14 and sotorasib (Lumakras) for KRAS G12C. The MET exon 14 skip mutation has attracted renewed atte…
…
continue reading
1
Mantle Cell Lymphoma: Optimizing Current Therapies
12:36
12:36
Play later
Play later
Lists
Like
Liked
12:36
Jonathan Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine, , joins OBR Editor-in-Chief Robert Figlin, MD, to talk about mantle cell lymphoma. Dr. Cohen describes the key to making a correct diagnosis and what the best frontline treatment approaches are for different patient groups. He also tal…
…
continue reading
1
COSMIC-313 trial and the Complex Treatment Landscape for Metastatic Renal Cell Cancer: How Do You Decide?
12:05
12:05
Play later
Play later
Lists
Like
Liked
12:05
Bob Figlin, MD, and Toni Choueiri, MD, the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discuss the early results from the COSMIC-313 trial, which Dr. Choueiri presented at ESMO 2022. The trial enrolled previously untreated patients with metastatic clear cell renal cell cancer who were classified as interm…
…
continue reading
1
Finding Joy in Work: ASCO’s Career Development Resources Help Trainees Choose Their Path
14:52
14:52
Play later
Play later
Lists
Like
Liked
14:52
Bob Figlin, MD, and Jamie Von Roenn, MD, discuss strategies for learning about the oncology specialty earlier in the training pipeline, particularly for under-represented groups. They also look at opportunities for oncology fellows to build skills in different career areas.
…
continue reading
1
Considering an Oncology Fellowship? Listen to This First
17:54
17:54
Play later
Play later
Lists
Like
Liked
17:54
Gerald Hsu, MD, PhD, UCSF’s hematology/oncology fellowship program director, joins Robert Figlin, MD, to talk about what fellowship programs are looking for in applicants, how trainees can find programs that are a good fit, and why preparing for an interview improves the odds you land at the right spot for you.…
…
continue reading
1
Kidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients
13:19
13:19
Play later
Play later
Lists
Like
Liked
13:19
Michael B. Atkins, MD, and Robert Figlin, MD, discuss results from the EVEREST clinical trial as well as new data on TKIs, immunotherapy, and HIF-2 inhibitors. They also discuss adjuvant therapy and how depth of response differs between immunotherapy and TKIs, and look ahead to what the future holds.…
…
continue reading
1
How to Choose CLL Treatments in the Frontline Setting
11:15
11:15
Play later
Play later
Lists
Like
Liked
11:15
Danielle Brander, MD, talks with Robert Figlin, MD, about selecting frontline treatments for CLL and how she talks with patients about their treatment options. “What I think is unique about the last few years is we’ve seen multiple randomized trials in the frontline setting that have shown not only superior progression-free survival … but several o…
…
continue reading
1
Rethinking HER2-Targeted Therapy After DESTINY-04
11:15
11:15
Play later
Play later
Lists
Like
Liked
11:15
William Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Annual Meeting, including results from DESTINY-Breast04 and new data on CDK4/6 inhibitors from the PALOMA-2 and MAINTAIN trials.
…
continue reading
1
Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immunotherapy
12:44
12:44
Play later
Play later
Lists
Like
Liked
12:44
Michael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melanoma. Data from the DREAMSeq trial, which Dr Atkins updated at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, show a significant survival advantage at two years for patients who r…
…
continue reading
1
Adjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What Agent
12:12
12:12
Play later
Play later
Lists
Like
Liked
12:12
Listen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including stage, EGFR mutation status, and PD-L1 status.…
…
continue reading